Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors.
about
Animal models for Ebola and Marburg virus infectionsVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesDevelopment of a new vaccine for the prevention of Lassa fever.Pharmacogenetic heterogeneity of transgene expression in muscle and tumoursComparison of replication-competent, first generation, and helper-dependent adenoviral vaccinesInfection and killing of multiple myeloma by adenovirusesBMP7 induces the differentiation of bone marrow-derived mesenchymal cells into chondrocytes.Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organsVaccination strategies for mucosal immune responsesLive attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.Rapid identification of human adenovirus types 3 and 7 from respiratory specimens via multiplex type-specific PCR.Strategies for engineering human chromosomes with therapeutic potential.Molecular epidemiology of adenovirus type 7 in the United States, 1966-2000Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.Characterization of species C human adenovirus serotype 6 (Ad6)Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.Genetic medicine strategies to protect against bioterrorism.Mining the adenovirus virome for oncolytics against multiple solid tumor typesSpecies D adenoviruses as oncolytics against B-cell cancers.Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies.An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirusAdenovirus as an emerging pathogen in immunocompromised patients.Efficacy of topical immunoglobulins against experimental adenoviral ocular infectionProspects for immunisation against Marburg and Ebola viruses.Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccinesCircumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.Evaluation of plasma inflammatory cytokine concentrations in racing sled dogs.Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboonsDisrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers.A myristoylated alanine-rich C kinase substrate-related peptide suppresses cytokine mRNA and protein expression in LPS-activated canine neutrophils.Development of vaccines for Marburg hemorrhagic fever.Circulating antibodies and macrophages as modulators of adenovirus pharmacologyGenome type analysis of adenovirus types 3 and 7 isolated during successive outbreaks of lower respiratory tract infections in children.Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.Postentry neutralization of adenovirus type 5 by an antihexon antibody.Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.An update on canine adenovirus type 2 and its vectors.Spectrum of viral infections in patients with cystic fibrosis.
P2860
Q21131118-D33FCE68-66D6-4586-9905-3455038B75DEQ21131585-7FA3330C-6550-4BCE-AC56-E0383AB235ACQ21563440-5B7FCD54-82A2-4695-B8B1-517380BA14E9Q24799710-E2EA9928-DB6D-4AF1-BE28-DD5218F0DC71Q33424498-580DCB2B-667E-434E-B7C0-ECB5C7582632Q33691833-483130D8-2FA3-47B1-B81C-51F532C85B67Q33787054-8A37293A-703F-472F-83B9-7675F47726E4Q33817535-A50B3F77-2850-467F-A877-52C03ED03312Q33975703-37362D8C-BBD4-46A3-B666-42E68533BE32Q33987611-5BC1F03E-3ABD-4B61-99EB-F55524D9DCB2Q34033557-65A8962B-910D-45C2-99AA-1B23C70C4CE3Q34143600-FCFD2F88-8695-469D-B0BC-350EE801EBDFQ34518173-BE7BBAA3-863F-48A7-8E33-4541BC180A50Q34583745-48C7C487-F3F3-4FE7-9F14-8B77B824F777Q34606818-A7584302-16CA-4C18-AB35-866A36A10010Q34669375-4A4D6B1E-874B-4D45-BC3A-1EFB94DB7DC3Q34701517-E4EABBD8-97A6-4B40-8D3B-E6C7AAF03032Q34767181-5DB4FBBB-9B5D-411A-9536-C132710182CDQ35223768-895F7975-01E0-4BCC-86B2-99E78FD52817Q35511348-23DB41A9-9132-4366-B723-4E95D4AA083DQ35596728-72A583EE-BBEA-4895-8E8A-3E2AEF7607FCQ35924750-2960521B-1DA9-4ABD-8C3E-1849A11A8EC1Q36003090-96E1431E-45F8-47BD-85A3-D3E7CCEA2334Q36087879-0ED15E7B-BD39-4C4C-B1E8-6127EFE89B79Q36088118-A1607E0F-841F-44D1-A016-F4C4A1FB2E9DQ36097089-C45A2244-EAB2-44B5-89A8-8835B2A77278Q36276187-FACF18A9-8DD2-4547-9B8A-EF352337CEA8Q36344638-AAC45500-46D3-4B19-B9D4-FB5133F50570Q36557727-8439E7CD-2551-4BDC-BAFE-045246C9B3D0Q36562614-4563D9E2-3966-40B7-BA0D-44A959830EEFQ36594178-73CA9003-6426-492D-B1C7-A89DB9D2FED9Q36703999-0B33A737-A407-4D26-87D7-D799F85165A9Q36728793-87681C9E-39D5-4159-AAF7-0894B197ED99Q36759761-E99F63CB-0F3E-452D-B503-F8369C91AD03Q36891908-E7CBC7CA-803B-4A3A-A9F0-40D775A09E9AQ37059464-F175FD53-4561-4ECE-AB3B-46CD6EE8D55FQ37596703-CD2F92FA-EF13-404B-ABC3-B00C1BB1DDF9Q37713960-D04320B7-D9FD-432B-A8C4-79937231D930Q37945220-DE7EAF18-CABA-4726-A921-AFAD804C9E99Q38201055-4C0BFD96-604A-4EA9-B8DE-A77E62856791
P2860
Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Incidence and prevalence of ne ...... erapy with adenovirus vectors.
@en
Incidence and prevalence of ne ...... erapy with adenovirus vectors.
@nl
type
label
Incidence and prevalence of ne ...... erapy with adenovirus vectors.
@en
Incidence and prevalence of ne ...... erapy with adenovirus vectors.
@nl
prefLabel
Incidence and prevalence of ne ...... erapy with adenovirus vectors.
@en
Incidence and prevalence of ne ...... erapy with adenovirus vectors.
@nl
P2093
P921
P356
P1433
P1476
Incidence and prevalence of ne ...... erapy with adenovirus vectors.
@en
P2093
P304
P356
10.1542/PEDS.101.6.1013
P407
P577
1998-06-01T00:00:00Z